CYSVIEW KIT
Peakhexaminolevulinate hydrochloride
NDAINTRAVESICALFOR SOLUTIONPriority Review
Approved
May 2010
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
CYSVIEW KIT (hexaminolevulinate hydrochloride) is precursor, aminolevulinic acid. First approved in 2010.
Drug data last refreshed 13h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSVIEW KIT is an intravesical imaging agent containing hexaminolevulinate hydrochloride, a precursor to photoactive porphyrins used for fluorescence-guided cystoscopy. After bladder instillation, it accumulates preferentially in neoplastic urothelial cells and fluoresces bright red under 360–450 nm light, enabling real-time visualization of bladder lesions. It is indicated for improving detection of non-muscle invasive bladder cancer during cystoscopy.
Peak11.2 years to LOE
Product is in peak commercial phase with established market presence; brand team likely sized for mature portfolio management and market defense.
Mechanism of Action
precursor, aminolevulinic acid. After bladder instillation, Cysview enters the bladder mucosa and is proposed to enter the intracellular space of mucosal cells where it is used as a precursor in the formation of the photoactive intermediate protoporphyrin IX (PpIX) and other photoactive porphyrins…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYSVIEW is a specialized niche diagnostic product with minimal linked job postings, reflecting its narrow indication and diagnostic (non-therapeutic) positioning. Career impact is strongest for professionals in urology-focused commercial, medical education, and niche hospital sales roles.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.